Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NMTi-ADC targeting HER2
- Development stage
- Preclinical
- Lead developer
- Myricx Bio
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
NMTi-ADC targeting HER2 is an investigational antibody-drug conjugate (ADC) developed by Myricx Bio. This drug consists of a selective and ultrapotent N-myristoyltransferase inhibitor (NMTi) payload conjugated via a cleavable linker to trastuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). The mechanism of action involves targeted delivery of the NMT inhibitor to HER2-expressing tumor cells, leading to inhibition of protein myristoylation—a process essential for cancer cell survival and proliferation. Preclinical studies have demonstrated complete efficacy and encouraging tolerability in rodent and non-human primate models. The primary indication under investigation is HER2-positive cancers[1][4].
- Other names
- HER2-NMTi ADCHER-2-NMTi ADCHER 2-NMTi ADCMYX2449MYX-2449MYX 2449
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)NMT1 (N-myristoyltransferase 1)NMT2 (N-myristoyltransferase 2)
Beyond the preview
Go deeper on NMTi-ADC targeting HER2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NMTi-ADC targeting HER2.